To include your compound in the COVID-19 Resource Center, submit it here.

NT-300: Phase III started

Romark began a double-blind, placebo-controlled, international Phase III trial to compare twice-daily 600 mg

Read the full 146 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE